Ascendis Pharma A/S (ASND)

NMS – Цена в реальном времени. Валюта: USD

260.75

-0.83 (-0.32%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

261.00

+0.25 (0.10%)

После закрытия: Jun 26, 2026, 4:48 PM EDT

13.06.2026

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

12.06.2026

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relative performance during the quarter were Vertiv Holdings, Ascendis Pharma, Howmet Aerospace, Diamondback Energy, and Roblox Corp. The largest detractors from relative performance during the quarter were Atlassian Corp., DoorDash Inc., Ares Management, Axon Enterprise, and MongoDB.

11.06.2026

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney, small intestine, CNS, and bone – as demonstrated by normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density.

08.06.2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

28.05.2026

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia.

09.05.2026

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

07.05.2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma.

Видео

08.12.2025

Neutral

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

Пресс-релизы

13.06.2026

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

11.06.2026

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

08.06.2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

07.05.2026

Ascendis Pharma A/S (ASND)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ascendis Pharma A/S (ASND)

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2026 Financial Results

Видео

Пресс-релизы

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2026 Financial Results

Видео

Пресс-релизы

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

Search stocks

Ascendis Pharma A/S (ASND)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ascendis Pharma A/S (ASND)

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2026 Financial Results

Видео

Пресс-релизы

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2026 Financial Results

Видео

Пресс-релизы

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma Reports First Quarter 2026 Financial Results